. 2014 Oct; 23(2):547-59.
doi: 10.1007/s00520-014-2459-x.

Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia

Sol Cortés de Miguel 1 Miguel Ángel Calleja-Hernández  Salomón Menjón-Beltrán  Inmaculada Vallejo-Rodríguez  
  • PMID: 25284722
  •     66 References
  •     6 citations


Myelosuppression secondary to chemotherapy remains a serious adverse effect of cancer therapy that causes high morbidity and mortality. Several current European and American guidelines recommend consideration of primary prophylaxis with colony-stimulating factors (CSFs) when the risk of febrile neutropenia is higher than 20 %. The main factors associated with a high risk of febrile neutropenia include the chemotherapy regimen, tumor type, and patient-related factors such as old age and/or comorbidities. The purpose of this paper is to summarize the most relevant clinical trials and updated recommendations of the main guidelines on the role of granulocyte colony-stimulating factors (G-CSFs) in febrile neutropenia, examining whether the combination of G-CSF with chemotherapy improves overall survival. Future directions for G-CSF use are also discussed.

Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy.
Bing-Bing Yang, Anna Kido, Atsuko Shibata.
Pharmacotherapy, 2007 Sep 28; 27(10). PMID: 17896894
Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
D Radosavljevic, I Golubicic, +2 authors, S Jelic.
J BUON, 2009 Aug 04; 14(2). PMID: 19650167
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.
Arnold L Potosky, Jennifer L Malin, +4 authors, Jane C Weeks.
J Natl Cancer Inst, 2011 Jun 15; 103(12). PMID: 21670423    Free PMC article.
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.
Alison G Freifeld, Eric J Bow, +8 authors, Infectious Diseases Society of America.
Clin Infect Dis, 2011 Jan 25; 52(4). PMID: 21258094
Highly Cited.
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.
Jeffrey Crawford, David C Dale, +4 authors, Gary H Lyman.
J Natl Compr Canc Netw, 2008 Mar 06; 6(2). PMID: 18319047
Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Maureen J Aarts, Frank P Peters, +17 authors, Vivianne C G Tjan-Heijnen.
J Clin Oncol, 2013 May 01; 31(34). PMID: 23630211
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.
Katy L Cooper, Jason Madan, +2 authors, Ron L Akehurst.
BMC Cancer, 2011 Sep 29; 11. PMID: 21943360    Free PMC article.
Systematic Review.
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Thomas J Smith, James Khatcheressian, +19 authors, Antonio C Wolff.
J Clin Oncol, 2006 May 10; 24(19). PMID: 16682719
Highly Cited.
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
F A Holmes, J A O'Shaughnessy, +10 authors, B C Liang.
J Clin Oncol, 2002 Feb 01; 20(3). PMID: 11821454
Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer.
Gary H Lyman, Richard L Barron, Jaime L Natoli, Ross M Miller.
Crit Rev Oncol Hematol, 2011 Jun 04; 81(3). PMID: 21636289
Systematic Review.
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.
V Trillet-Lenoir, J Green, +7 authors, D Tomita.
Eur J Cancer, 1993 Jan 01; 29A(3). PMID: 7691119
Highly Cited.
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.
Nicole M Kuderer, David C Dale, +2 authors, Gary H Lyman.
Cancer, 2006 Apr 01; 106(10). PMID: 16575919
Highly Cited.
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.
Jorge Sierra, Jeffrey Szer, +7 authors, Alberto Bosi.
BMC Cancer, 2008 Jul 12; 8. PMID: 18616811    Free PMC article.
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
J Crawford, C Caserta, F Roila, ESMO Guidelines Working Group.
Ann Oncol, 2010 Jun 29; 21 Suppl 5. PMID: 20555091
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.
G von Minckwitz, S Kümmel, +14 authors, German Breast Group.
Ann Oncol, 2007 Sep 12; 19(2). PMID: 17846019
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.
J Klastersky, M Paesmans, +8 authors, J Talcott.
J Clin Oncol, 2000 Aug 16; 18(16). PMID: 10944139
Highly Cited.
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
Nicole M Kuderer, David C Dale, Jeffrey Crawford, Gary H Lyman.
J Clin Oncol, 2007 Jul 20; 25(21). PMID: 17634496
Highly Cited. Systematic Review.
Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
José Ignacio Mayordomo, Andrés López, +8 authors, ENIA Study Group.
Curr Med Res Opin, 2009 Sep 03; 25(10). PMID: 19722781
The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.
G H Lyman, D C Dale, +5 authors, J Crawford.
Ann Oncol, 2013 Jun 22; 24(10). PMID: 23788754    Free PMC article.
Systematic Review.
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.
G Bonadonna, P Valagussa, +2 authors, C Brambilla.
N Engl J Med, 1995 Apr 06; 332(14). PMID: 7877646
Highly Cited.
Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
Derek Weycker, James Hackett, +2 authors, Andrew G Glass.
Ann Pharmacother, 2006 Feb 24; 40(3). PMID: 16492793
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.
Otavio A C Clark, Gary H Lyman, +2 authors, Benjamin Djulbegovic.
J Clin Oncol, 2005 Jun 18; 23(18). PMID: 15961767
A prospective investigation of chemotherapy-induced neutropenia and quality of life.
Barry V Fortner, Arthur C Houts, Lee S Schwartzberg.
J Support Oncol, 2006 Nov 04; 4(9). PMID: 17080736
Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics.
John R Wingard, Mohamed Elmongy.
Crit Rev Oncol Hematol, 2009 Feb 25; 72(2). PMID: 19237297
Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.
Cesare Gridelli, Matti S Aapro, +9 authors, Filippo De Marinis.
Crit Rev Oncol Hematol, 2007 Mar 21; 63(1). PMID: 17368037
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Luisa Bonilla, Irit Ben-Aharon, +3 authors, Salomon M Stemmer.
J Natl Cancer Inst, 2010 Nov 26; 102(24). PMID: 21098761    Free PMC article.
Systematic Review.
Lineage-specific hematopoietic growth factors.
Kenneth Kaushansky.
N Engl J Med, 2006 May 12; 354(19). PMID: 16687716
Highly Cited. Review.
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Julia Bohlius, Christine Herbst, +2 authors, Andreas Engert.
Cochrane Database Syst Rev, 2008 Oct 10; (4). PMID: 18843642    Free PMC article.
Systematic Review.
Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.
Gary H Lyman, Nicole M Kuderer, +4 authors, David C Dale.
Cancer, 2011 Apr 22; 117(9). PMID: 21509769    Free PMC article.
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.
G P Bodey, M Buckley, Y S Sathe, E J Freireich.
Ann Intern Med, 1966 Feb 01; 64(2). PMID: 5216294
Highly Cited.
Management of fever in patients with cancer and treatment-induced neutropenia.
P A Pizzo.
N Engl J Med, 1993 May 06; 328(18). PMID: 8469254
Highly Cited. Review.
Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia.
C Zwick, F Hartmann, +11 authors, German High-Grade Non-Hodgkin Lymphoma Study Group.
Ann Oncol, 2011 Feb 05; 22(8). PMID: 21292644
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America.
W T Hughes, D Armstrong, +7 authors, L S Young.
Clin Infect Dis, 1997 Oct 06; 25(3). PMID: 9314442
Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: a systematic review and meta-analysis.
Yee Mei Lee, Craig Lockwood.
Int J Nurs Pract, 2013 Dec 18; 19(6). PMID: 24330206
Systematic Review.
Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium.
J L Gabrilove, A Jakubowski, +7 authors, H F Oettgen.
J Clin Invest, 1988 Oct 01; 82(4). PMID: 2459163    Free PMC article.
Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Derek Weycker, Jennifer Malin, +4 authors, Gerry Oster.
Clin Ther, 2009 Jun 23; 31(5). PMID: 19539108
The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs).
Matteo Lambertini, Lucia Del Mastro, Andrea Bellodi, Paolo Pronzato.
Crit Rev Oncol Hematol, 2013 Sep 18; 89(1). PMID: 24041627
Antimicrobial prophylaxis in febrile neutropenia.
Minoru Yoshida, Ryuzo Ohno.
Clin Infect Dis, 2004 Jul 14; 39 Suppl 1. PMID: 15250025
Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.
Gary H Lyman, David C Dale, +4 authors, Jeffrey Crawford.
J Clin Oncol, 2010 Apr 14; 28(17). PMID: 20385991
Systematic Review.
Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Johanna N Timmer-Bonte, Theo M de Boo, +9 authors, Vivianne C Tjan-Heijnen.
J Clin Oncol, 2005 Nov 01; 23(31). PMID: 16258098
Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy.
Mi Rim Choi, Craig A Solid, +4 authors, Thomas J Arneson.
Support Care Cancer, 2014 Feb 05; 22(6). PMID: 24492928
Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
Gary H Lyman, David C Dale, Jeffrey Crawford.
J Clin Oncol, 2003 Dec 16; 21(24). PMID: 14673039
Highly Cited.
Quality of life and chemotherapy-induced neutropenia.
Geraldine Padilla, Mary E Ropka.
Cancer Nurs, 2005 May 26; 28(3). PMID: 15915058
Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
William G Martin, Kay M Ristow, +3 authors, Stephen M Ansell.
J Clin Oncol, 2005 Sep 28; 23(30). PMID: 16186594
Splenic rupture in a patient with plasma cell myeloma following G-CSF/GM-CSF administration for stem cell transplantation and review of the literature.
R Veerappan, M Morrison, S Williams, D Variakojis.
Bone Marrow Transplant, 2007 Jun 15; 40(4). PMID: 17563733
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
M D Green, H Koelbl, +12 authors, International Pegfilgrastim 749 Study Group.
Ann Oncol, 2002 Dec 19; 14(1). PMID: 12488289
Highly Cited.
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study.
Gianni Bonadonna, Angela Moliterni, +4 authors, Pinuccia Valagussa.
BMJ, 2005 Jan 15; 330(7485). PMID: 15649903    Free PMC article.
Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.
Isabel Chirivella, Begoña Bermejo, +7 authors, Ana Lluch.
Breast Cancer Res Treat, 2008 May 09; 114(3). PMID: 18463977
Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer.
Anders Jakobsen, Ake Berglund, +9 authors, Nordic Gastrointestinal Tumour Therapy Group, Norway, Sweden and Denmark.
Acta Oncol, 2003 Jan 28; 41(6). PMID: 12546525
American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology.
Lowell E Schnipper, Thomas J Smith, +4 authors, Dana S Wollins.
J Clin Oncol, 2012 Apr 12; 30(14). PMID: 22493340
Highly Cited. Review.
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
J Crawford, H Ozer, +7 authors, G Rausch.
N Engl J Med, 1991 Jul 18; 325(3). PMID: 1711156
Highly Cited.
Optimal timing (Preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide.
G Koumakis, M Vassilomanolakis, +5 authors, A P Efremidis.
Oncology, 1999 Jan 14; 56(1). PMID: 9885374
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Marc L Citron, Donald A Berry, +18 authors, Larry Norton.
J Clin Oncol, 2003 Apr 02; 21(8). PMID: 12668651
Highly Cited.
Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.
V C Tjan-Heijnen, B Biesma, +4 authors, P E Postmus.
J Clin Oncol, 1998 Aug 15; 16(8). PMID: 9704721
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
M S Aapro, J Bohlius, +10 authors, European Organisation for Research and Treatment of Cancer.
Eur J Cancer, 2010 Nov 26; 47(1). PMID: 21095116
Highly Cited. Systematic Review.
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia.
L C Hartmann, L K Tschetter, +9 authors, C G Moertel.
N Engl J Med, 1997 Jun 19; 336(25). PMID: 9187067
Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.
A Bosly, D Bron, +6 authors, G Verhoef.
Ann Hematol, 2007 Oct 24; 87(4). PMID: 17952688
Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
Arash Naeim, Henry J Henk, +4 authors, Robert Deeter.
BMC Cancer, 2013 Jan 10; 13. PMID: 23298389    Free PMC article.
Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.
Howard A Burris, Chandra P Belani, +6 authors, Alan Saven.
J Oncol Pract, 2010 Sep 03; 6(3). PMID: 20808556    Free PMC article.
Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy.
Shane D Scott, Elizabeth A Chrischilles, +3 authors, Bradley S Stolshek.
J Manag Care Pharm, 2003 Nov 14; 9(2 Suppl). PMID: 14613340
Benefits of GM-CSF Versus Placebo or G-CSF in Reducing Chemotherapy-Induced Complications: A Systematic Review of the Literature.
Robert W Dubois, Lionel A Pinto, +2 authors, Gary H Lyman.
Support Cancer Ther, 2008 Jul 17; 2(1). PMID: 18628156
Risk models for predicting chemotherapy-induced neutropenia.
Gary H Lyman, Christopher H Lyman, Olayemi Agboola.
Oncologist, 2005 Jun 22; 10(6). PMID: 15967836
Systematic Review.
Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice.
K Krzemieniecki, P Sevelda, +7 authors, J Maenpaa.
Support Care Cancer, 2013 Oct 25; 22(3). PMID: 24154740    Free PMC article.
Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States).
Shari Chen-Hardee, Elizabeth A Chrischilles, +4 authors, David Delgado.
Cancer Causes Control, 2006 Apr 25; 17(5). PMID: 16633911
Epidemiology of febrile neutropenia.
Gary H Lyman, Nicole M Kuderer.
Support Cancer Ther, 2008 Jul 17; 1(1). PMID: 18628128
Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor.
S B Saxman, C R Nichols, L H Einhorn.
Chest, 1997 Mar 01; 111(3). PMID: 9118704
G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
Umberto Vitolo, Francesco Angrili, +2 authors, Massimo Federico.
Med Oncol, 2016 Nov 09; 33(12). PMID: 27822615
Effect of Nigella sativa seed administration on prevention of febrile neutropenia during chemotherapy among children with brain tumors.
HebatAlla Fathi Mohamed Mousa, Nesrin Kamal Abd-El-Fatah, +2 authors, Shady Hassan Fadel.
Childs Nerv Syst, 2017 Mar 30; 33(5). PMID: 28349493
Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Isabel Puértolas, Alberto Frutos Pérez-Surio, +2 authors, María Del Tránsito Salvador.
Eur J Clin Pharmacol, 2017 Nov 21; 74(3). PMID: 29152672
Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy.
Jihyoun Lee, Jong Eun Lee, +5 authors, Cheol Wan Lim.
Ann Surg Treat Res, 2018 May 08; 94(5). PMID: 29732352    Free PMC article.
Prescribing patterns from medical chart abstraction of patients administered lipegfilgrastim: a pilot study in Europe.
Sigal Kaplan, Nicole Lang, +3 authors, Emanuele Borroni.
J Drug Assess, 2019 May 21; 8(1). PMID: 31105989    Free PMC article.
The Efficacy of Moxibustion for Breast Cancer Patients with Chemotherapy-Induced Myelosuppression during Adjuvant Chemotherapy: A Randomized Controlled Study.
Yajie Ji, Siyu Li, +12 authors, Xiaohong Xue.
Evid Based Complement Alternat Med, 2021 May 15; 2021. PMID: 33986813    Free PMC article.